The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies

Cancer Biomark. 2022;33(4):449-465. doi: 10.3233/CBM-210382.


The Early Detection Research Network's (EDRN) purpose is to discover, develop and validate biomarkers and imaging methods to detect early-stage cancers or at-risk individuals. The EDRN is composed of sites that fall into four categories: Biomarker Developmental Laboratories (BDL), Biomarker Reference Laboratories (BRL), Clinical Validation Centers (CVC) and Data Management and Coordinating Centers. Each component has a crucial role to play within the mission of the EDRN. The primary role of the CVCs is to support biomarker developers through validation trials on promising biomarkers discovered by both EDRN and non-EDRN investigators. The second round of funding for the EDRN Lung CVC at Vanderbilt University Medical Center (VUMC) was funded in October 2016 and we intended to accomplish the three missions of the CVCs: To conduct innovative research on the validation of candidate biomarkers for early cancer detection and risk assessment of lung cancer in an observational study; to compare biomarker performance; and to serve as a resource center for collaborative research within the Network and partner with established EDRN BDLs and BRLs, new laboratories and industry partners. This report outlines the impact of the VUMC EDRN Lung CVC and describes the role in promoting and validating biological and imaging biomarkers.

Keywords: Lung cancer; biomarkers; early detection research network; validation.

MeSH terms

  • Biomarkers, Tumor*
  • Early Detection of Cancer*
  • Humans
  • Lung Neoplasms* / diagnosis
  • Validation Studies as Topic


  • Biomarkers, Tumor